多款新冠疫苗保护力超90%,为什么还需要继续同时研发上百种疫苗?
▎药明康德内容团队编辑
图片来源:123RF
需要适合不同人群的不同疫苗
图片来源:123RF
需要生产足够数量的疫苗来保护人群
图片来源:123RF
需要疫苗能覆盖每个人、每个角落
需要能够公平分配疫苗
新冠研究相关报道:
题图来源:药明康德内容团队制图
参考资料(可上下滑动查看)
[1] Why we need multiple vaccines for COVID-19. Retrieved November 24, 2020, from https://medicalxpress.com/news/2020-11-multiple-vaccines-covid-.html
[2] COVAX explained. Retrieved November 24, 2020, from https://www.gavi.org/vaccineswork/covax-explained
[3] Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273). Retrieved November 24, 2020, from https://investors.modernatx.com/news-releases/news-release-details/moderna-has-completed-case-accrual-first-planned-interim
[4] Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures. Retrieved November 24, 2020, from https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-longer-shelf-life-its-covid-19-vaccine
[5] Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. Retrieved November 24, 2020, from https://www.businesswire.com/news/home/20201109005539/en
[6] AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19, Retrieved November 23, 2020, from https://www.astrazeneca.com/content/dam/az/media-centre-docs/press-releases/2020/AZD1222-HLR-RNS.pdf
[7] 疫情中开发疫苗,就像一边飞行一边造飞机 | 药明康德线上论坛实录. Retrieved November 24, 2020, from https://mp.weixin.qq.com/s/H5Tl6fSH8YB919UiqgMNTQ
[8] Roy M Anderson, et al., (2020). Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. The Lancet, DOI:https://doi.org/10.1016/S0140-6736(20)32318-7
注:本文旨在介绍医药健康研究进展,不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。
版权说明:本文来自药明康德微信团队,欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医学新视点」微信公众号后台回复“转载”,获取转载须知。
如有其他合作需求,请联系wuxi_media@wuxiapptec.com
点“在看”,分享医学新知